Chris Garabedian

Loading Events

← Back to Events

Chris Garabedian

Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept.  In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and launched the Perceptive Xontogeny Venture Fund in 2018 to support early stage companies seeded and incubated at Xontogeny and other ventures.

Chris has a broad base of experience and a track record of success over his decades long experience in the biopharma industry. Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial stage leader in the genetic technology space after leading the development of the company’s Duchenne Muscular Dystrophy program.  Prior to Sarepta, Chris led Corporate Strategy for Celgene from 2007 to 2010. Prior to Celgene, Chris served in a number of global commercial and corporate development leadership roles at Gilead from 1997 to 2005.

Chris serves on a number of Boards of life sciences companies and speaks at industry conferences on a wide range of important issues.  Chris is also on the Board of Directors of MassBio and serves as a Senior Advisor for the Boston Consulting Group.

October 2020

Oct
22
Thu

Fourth Annual PE/VC Conference: Perspectives from Allocators and Managers

This conference brings together leading private markets allocators, consultants and fund managers who focus on private equity, private credit, growth equity, and venture capital to learn how they select winners, add value and deliver returns.

Find out more »
Alternative Investments, Fintech Thought Leadership Group
+ Export Events